Glycine Proline Formulation for Radiation Mucositis Pain and Scarring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for oral mucositis induced by radiation or chemotherapy lack a universally accepted standard, and existing therapies often fail to effectively manage pain and prevent fibrotic scarring, leading to adverse impacts on patients' quality of life and treatment outcomes.
Innovation Solution
A formulation combining glycine, proline, and optionally a natural or synthetic film-forming polymer, such as hyaluronic acid, along with lysine and/or leucine, which enhances gene expression of e-NO Synthase and VEGF, controls collagen synthesis by fibroblasts, and suppresses TGF beta expression to prevent fibrotic scarring, providing rapid pain relief and accelerating wound healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (topical anesthetics, systemic analgesics, anti-inflammatories) are used for oral mucositis, then pain management is provided, but fibrotic scarring is not prevented and pain relief is not rapid
Solution Approach 1:
The invention uses a composite formulation combining multiple amino acids (glycine, proline, lysine, leucine) with hyaluronic acid to achieve both pain relief and prevention of fibrotic scarring. This composite approach allows synergistic effects where the amino acid combination modulates TGF-beta expression to prevent fibrosis while hyaluronic acid provides pain relief and tissue regeneration support.
Solution Approach 2:
The invention changes the biochemical parameters of the wound healing process by introducing specific amino acids that modify gene expression (e-NO Synthase, VEGF) and protein production (TGF beta). This parameter modification shifts the healing trajectory from fibrotic scarring to regenerative healing, while also providing rapid pain relief through biochemical modulation.
2Productivity
If hyaluronic acid is used alone for wound healing, then tissue repair is promoted, but fibrotic scarring is not prevented
Solution Approach 1:
The invention combines hyaluronic acid with a specific combination of amino acids (glycine, proline, lysine, leucine) to create a composite formulation that achieves both rapid wound healing and prevention of fibrotic scarring. The amino acids work synergistically with hyaluronic acid to modulate the healing process and prevent excessive collagen deposition.
Solution Approach 2:
The amino acids act as intermediaries that mediate between the initial wound healing response and the final tissue outcome. They modulate TGF-beta expression and collagen synthesis by fibroblasts, serving as biochemical mediators that prevent the transition from regenerative healing to fibrotic scarring while maintaining rapid wound closure.
3Ease of operation
If standard treatments are continued for oral mucositis, then pain is managed, but treatment discontinuation or dose reduction occurs due to severity
Solution Approach 1:
The invention applies preliminary action by providing rapid pain relief within 2 hours of administration, which prevents the escalation of pain to debilitating levels. This early and effective pain control allows patients to continue their cancer treatment without discontinuation or dose reduction, maintaining treatment continuity and quality of life.
4Adaptability or versatility
If no standardized treatment strategy is available for oral mucositis, then treatment options are limited, but patient outcomes and quality of life are adversely affected
Solution Approach 1:
The invention provides a standardized composite formulation that combines multiple active ingredients (amino acids and hyaluronic acid) in specific proportions. This standardized composite approach creates a reliable, reproducible treatment strategy that can be universally applied to oral mucositis patients, improving both treatment adaptability and patient outcomes.
Data Source
AI summary
The present invention relates to the use of a combination of glycine, proline, and optionally a natural or synthetic film-forming polymer, and/or lysine and/or leucine, to prepare a composition for the treatment of mucositis induced by radiation or chemotherapy.